Array Biopharma (ARRY) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 -4.25%
EPS Growth %: -70.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -70.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.16), $0.04 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $43 million versus the consensus estimate of $30.35 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
